We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+20.07%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$530M
AUM Growth
-$28.3M
Cap. Flow
-$54.8M
Cap. Flow %
-10.35%
Top 10 Hldgs %
67.2%
Holding
99
New
35
Increased
16
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
KDMN
Kadmon Holdings, Inc.
KDMN
+$5.65M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$5.31M
3
VRAY
ViewRay, Inc.
VRAY
+$4.67M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$4.21M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.69M

Top Sells

Rank Stock Value
1
DBVT
DBV Technologies
DBVT
+$8.15M
2
FOLD
Amicus Therapeutics
FOLD
+$3.52M
3
NVTA
Invitae Corporation
NVTA
+$3.37M
4
FBRX icon
Forte Biosciences
FBRX
+$3.13M
5
PDSB icon
PDS Biotechnology
PDSB
+$3.11M

Sector Composition

Rank Sector Weight
1 Healthcare 51.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$109M 20.59%
6,750,000
+12,294
+0.2% +$145K
ASMB icon
2
Assembly Biosciences
ASMB
$503M
$49.2M 9.29%
90,592
+7,259
+9% +$3.29M
IWM icon
3
PUT
iShares Russell 2000 ETF
IWM
$81.5B
$38.1M 7.2%
250,000
-215,000
-46% -$32.3M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$1.93B
$31.1M 5.88%
3,892,000
+460,191
+13% +$3.69M
XBI icon
5
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$29.7M 5.61%
350,000
-210,000
-38% -$17.6M
VCYT icon
6
Veracyte
VCYT
$3.58B
$21.5M 4.06%
3,295,111
– –
ASND icon
7
Ascendis Pharma A/S
ASND
$16B
$21.3M 4.02%
531,000
+31,000
+6% +$1.13M
ARGX icon
8
argenx
ARGX
$52B
$20.4M 3.85%
323,000
+106,745
+49% +$3.5M
KDMN
9
DELISTED
Kadmon Holdings, Inc.
KDMN
$17.8M 3.36%
4,915,000
+1,581,667
+47% +$5.65M
VRAY
10
DELISTED
ViewRay, Inc.
VRAY
$17.7M 3.35%
1,915,654
+583,671
+44% +$4.67M
IRIX icon
11
IRIDEX
IRIX
$14.4M
$15.2M 2.88%
2,000,000
– –
CEMI
12
DELISTED
Chembio diagnostics, Inc.
CEMI
$14.1M 2.66%
1,721,299
– –
INDP icon
13
Indaptus Therapeutics
INDP
$175M
$14M 2.65%
1,216
– –
ZGNX
14
DELISTED
Zogenix, Inc.
ZGNX
$12M 2.27%
300,000
+50,000
+20% +$1.92M
PDSB icon
15
PDS Biotechnology
PDSB
$40M
$8.84M 1.67%
47,195
-15,475
-25% -$3.11M
GYRE icon
16
Gyre Therapeutics
GYRE
$681M
$6.14M 1.16%
+60,000
New +$3.06M
AVXS
17
DELISTED
AveXis, Inc. Common Stock
AVXS
$5.85M 1.11%
+52,900
New +$5.31M
EVH icon
18
Evolent Health
EVH
$353M
$5.17M 0.98%
420,000
-30,000
-7% -$423K
FXI icon
19
PUT
iShares China Large-Cap ETF
FXI
$4.35B
$4.62M 0.87%
100,000
– –
BCRX icon
20
BioCryst Pharmaceuticals
BCRX
$2.24B
$4.42M 0.83%
900,000
-96,300
-10% -$467K
MNTA
21
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.34M 0.82%
+311,169
New +$4.21M
SGEN
22
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$4.28M 0.81%
80,000
+40,000
+100% +$2.34M
CASM
23
DELISTED
CAS Medical Systems, Inc.
CASM
$3.97M 0.75%
5,160,000
+66,724
+1% +$48.8K
NBRV
24
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.47M 0.65%
2,320
+720
+45% +$1.14M
GBT
25
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.15M 0.59%
+80,000
New +$2.99M
1
2 3 4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2017 Portfolio in Review

As of Q4 2017, Acuta Capital Partners held 99 positions worth $530M, down 5.1% from $558M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Acuta Capital Partners withdrew a net $54.8M in Q4 2017, closing 25 positions and reducing 15 holdings. Its most notable exit was DBV Technologies, an estimated $8.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 47% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in AveXis, Inc. Common Stock worth $5.85M.

  • Acuta Capital Partners's largest Q4 2017 buy was AveXis, Inc. Common Stock: 52,900 shares worth $5.85M.
  • Acuta Capital Partners added most to Kadmon Holdings, Inc. in Q4 2017, an estimated $5.65M increase.
  • Acuta Capital Partners's biggest Q4 2017 reduction was Amicus Therapeutics, cutting an estimated $3.52M.
  • Acuta Capital Partners fully exited DBV Technologies in Q4 2017, selling an estimated $8.15M.
  • Acuta Capital Partners's ten largest holdings make up 67% of its $530M portfolio in Q4 2017.
  • Acuta Capital Partners opened 35 new positions and closed 25 in Q4 2017.
  • Acuta Capital Partners's portfolio value fell 5.1% quarter-over-quarter to $530M.

Based on Acuta Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.